Form 4 for SLDB Solid Biosciences Inc.
Accepted 2023-06-08 00:00:00 ET · period of report 2023-05-02 · accession 0000899243-23-014999 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-06-08 | 2023-06-02 | SLDB | Ganot Ilan | Dir | M - OptEx | — | +1,583 | 87.8K | +2% | — |
| DI | 2023-06-08 | 2023-05-02 | SLDB | Ganot Ilan | Dir | S - Sale+OE | $4.85 | -487 | 4,153 | -10% | -$2,362 |
| DI | 2023-06-08 | 2023-05-02 | SLDB | Ganot Ilan | Dir | M - OptEx | — | +1,553 | 4,640 | +50% | — |
| DI | 2023-06-08 | 2023-05-02 | SLDB | Ganot Ilan | Dir | M - OptEx | $0.00 | -1,553 | 1,553 | -50% | $0 |
| D | 2023-06-08 | 2023-06-06 | SLDB | Ganot Ilan | Dir | A - Grant | $0.00 | +9,650 | 9,650 | New | $0 |
| D | 2023-06-08 | 2023-06-02 | SLDB | Ganot Ilan | Dir | M - OptEx | $0.00 | -1,583 | 3,166 | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-02 | M | A | 1,583 | — | 87,758 | D | — | — | (F1) Restricted stock units convert into common stock on a one-for-one basis. (F4) Represents 83,716 shares held by Mr. Ganot as an individual, and 4,042 shares held by Mr. Ganot and Annie Ganot as joint tenants with right of survivorship. |
| 2 | Common | Common Stock | 2023-05-02 | S | D | 487 | $4.85 | 4,153 | I Wife | — | — | (F3) This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1). (F2) Includes 1,709 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 31, 2023. |
| 3 | Common | Common Stock | 2023-05-02 | M | A | 1,553 | — | 4,640 | I Wife | — | — | (F1) Restricted stock units convert into common stock on a one-for-one basis. (F2) Includes 1,709 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 31, 2023. |
| 4 | Derivative | Restricted Stock Units | 2023-05-02 | M | D | 1,553 | $0.00 | 1,553 | I Wife | — · — to — | 1,553 Common Stock | (F1) Restricted stock units convert into common stock on a one-for-one basis. (F6) The restricted stock units were granted on May 2, 2022 and vest in two equal annual installments beginning on the first anniversary of the grant date. |
| 5 | Derivative | Director Stock Option (Right to Buy) | 2023-06-06 | A | A | 9,650 | $0.00 | 9,650 | D | $6.37 · — to 2033-06-06 | 9,650 Common Stock | (F8) This option was granted on June 6, 2023 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. |
| 6 | Derivative | Restricted Stock Units | 2023-06-02 | M | D | 1,583 | $0.00 | 3,166 | D | — · — to — | 1,583 Common Stock | (F1) Restricted stock units convert into common stock on a one-for-one basis. (F7) On December 2, 2022 (the "Grant Date"), Mr. Ganot was granted 6,333 restricted stock units, vesting in equal quarterly installments with the first installment vesting three months from the Grant Date and the final installment vesting date being the date that is 12 months from the Grant Date; provided that in the event of a change in control the restricted stock units shall accelerate in full. |